MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

Core Viewpoint - MediPharm Labs Corp. announces the resignation of CEO David Pidduck, effective January 23, 2026, with CFO Greg Hunter appointed as Interim CEO while the Board evaluates long-term leadership plans [1][2]. Group 1: Leadership Transition - David Pidduck has been instrumental in stabilizing and repositioning the company, successfully executing restructuring initiatives and improving profitability [2]. - Greg Hunter, appointed as Interim CEO, has a strong background in financial management and has implemented cost-reduction initiatives, enhancing financial and operational controls since becoming CFO in February 2021 [3][4]. - The Board expresses confidence in Hunter's ability to drive execution and operational discipline during this transition period [5]. Group 2: Company Background - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and advanced derivative products in a GMP-certified facility [6]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale, domestic GMP license for extracting multiple natural cannabinoids [7]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to Canadian medical patients and enhancing its international operations [8].